Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12613000026729
ACTRN12613000026729
Terminated
Not Applicable

An investigation of the effects of intranasal oxytocin on socio-emotional brain regions in Huntington’s disease

Monash Biomedical Imaging0 sites40 target enrollmentJanuary 9, 2013
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Monash Biomedical Imaging
Enrollment
40
Status
Terminated
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 9, 2013
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Monash Biomedical Imaging

Eligibility Criteria

Inclusion Criteria

  • •For Healthy controls: Males; Right\-handed; between the ages of 25\-55 years; non\-smoker and no drug/alcohol abuse; medication free; and no metal objects present in body (or which can't be removed or which is not MRI safe).
  • •For Huntington's disease (HD): As above plus a diagnosis of the disease is required.

Exclusion Criteria

  • •Clinically significant medical or neurological condition (other than HD for the patients), significant head injury (or loss of consciousness from longer than 5 mins), presence of ferrous\-containing metals within the body, inability to tolerate small enclosed spaces without anxiety.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
An investigation of the effects of intranasal oxytocin spray on socio-emotional brain regions in ageing in healthy adults.Nil - Healthy Ageingil - Healthy AgeingNeurological - Studies of the normal brain and nervous system
ACTRN12615001148561Australian Catholic University Research140
Not yet recruiting
Not Applicable
An investigation of the effects of intranasal oxytocin spray on socio-emotional brain regions in participants with Body Dysmorphic Disorder.
ACTRN12614000991617Prof Susan Rossell64
Active, not recruiting
Phase 1
Oxytocin intranasal administrations in children with Prader-Willi syndrome aged from 3 to 12 years.
EUCTR2016-003273-18-FRniversity Hospital of Toulouse40
Completed
Phase 3
Evaluation of Intranasal oxytocine spray effect on preventing post-dural puncture headache after cesarean sectiopost-dural puncture headache.Spinal and epidural anesthesia-induced headache during the puerperiumO89.4
IRCT20201215049725N1Karaj University of Medical Sciences170
Not yet recruiting
Phase 2
Oxytocin & benzodiazepines
2024-516262-11-00St. Olavs Hospital HF60